Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03387176 |
Recruitment Status :
Recruiting
First Posted : December 29, 2017
Last Update Posted : May 26, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Nephrotic Syndrome | Other: Implementation of a gluten-free diet |
Study Type : | Observational |
Estimated Enrollment : | 40 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker |
Actual Study Start Date : | December 1, 2017 |
Estimated Primary Completion Date : | September 2021 |
Estimated Study Completion Date : | September 2021 |

Group/Cohort | Intervention/treatment |
---|---|
zonulin ≤17.5 ng/ml
Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
|
Other: Implementation of a gluten-free diet
Patients will be placed on gluten free diet for 9-12 months. |
zonulin >17.5 ng/ml
Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
|
Other: Implementation of a gluten-free diet
Patients will be placed on gluten free diet for 9-12 months. |
- Change in disease activity measured by relapse rate [ Time Frame: 12 Months ]Response is defined as a ≥50%decrease in relapse rate
- Change in disease activity measured by change in dosage of corticosteroids and immunosuppressive medications [ Time Frame: 12 Months ]reduction by ≥1 drug in exposure to immunosuppressive medications in response to the GFD

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 9 Months to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Steroid sensitive NS: complete remission of proteinuria in response to administration of a standard course of corticosteroids
- Difficult-to-manage NS: disease that cannot be controlled without incurring intolerable side effects from currently available immunosuppressive agents, namely corticosteroids, calcineurin inhibitors, mycophenolate mofetil, or rituximab. Patients with biopsy-proven MCD or FSGS will be eligible as long as they have steroid sensitive disease. However, a renal biopsy will not be required for enrollment into the trial.
Exclusion Criteria:
- Any patient diagnosed with nephrotic syndrome that is not considered steroid sensitive or frequently relapsing
- Pre-existing celiac disease or gastro-intestinal disorder that precludes use of a GFD

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03387176
Contact: Suzanne Vento | 646 501 2665 | Suzanne.Vento@nyumc.org |
United States, New York | |
New York University School of Medicine | Recruiting |
New York, New York, United States, 10016 | |
Contact: Suzanne Vento, MD 646-501-2665 Suzanne.Vento@nyumc.org | |
Principal Investigator: Howard Trachtman, MD |
Principal Investigator: | Howard Trachtman, MD | NYU Langone Health |
Responsible Party: | NYU Langone Health |
ClinicalTrials.gov Identifier: | NCT03387176 |
Other Study ID Numbers: |
17-01307 |
First Posted: | December 29, 2017 Key Record Dates |
Last Update Posted: | May 26, 2020 |
Last Verified: | May 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Nephrotic Syndrome Nephrosis Syndrome Disease |
Pathologic Processes Kidney Diseases Urologic Diseases |